Drug Information Related to Adagen
Back
01. Enzon Pharmaceuticals Secures Supply of Oncaspar. - Free Online Librar...
Important Outcome for Children with ALL BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced it entered into an agreement with Ovation Pharmaceuticals, Inc. for the supply of the active ingredient used in the production of Enzon's Oncaspar...
02. Enzon and Micromet Announce Strategic Collaboration for Novel Single ....
Business Editors and Medical/Health WritersPISCATAWAY, N.J. and MUNICH, Germany--(BUSINESS WIRE)--April 10,
2002- Partnership Creates the Leading Platform for Next Generationof Antibody Therapeutics -Enzon, Inc. (NASDAQ:ENZN) and Micromet AG (private) announced today...
03. Amicable Settlement Reached Between Axiom Worldwide and Adagen Medical...
TAMPA, Fla. -- Axiom Worldwide and Adagen Medical announce that an
amicable settlement has been reached in litigation filed by the two
companies in Georgia and Florida. For a number of years, Adagen has been
a competitor of Axiom in the spinal decompression marke...
04. Enzon Reports Certain Financial and Other Information for Fourth ......
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today reported certain financial and other business highlights for the quarter ended June 30, 2005, the fourth quarter of Enzon's fiscal year (FY) 2005. As previously reported in a Form 8-K and press rel...
05. Enzon Reports Third Quarter Results. - Free Online Library
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN)
today announced its financial results for the quarter ended March 31,
2005, the third quarter of Enzon's fiscal year (FY FY - Feng Yun SatelliteFY - Fight Yard (gaming, Counter-Strike)FY - Financial Yea...
06. Enzon reports third quarter results. - Free Online Library
PISCATAWAY, N.J.--(BUSINESS WIRE)--May 16, 1997--Enzon, Inc.
(NASDAQNMS:ENZN) announced today a net loss of $1,992,000 or $0.07 per
share for the three months ended March 31, 1997 compared to a net loss
of $1,994,000 or $0.08 per share for the comparable quarter ...
07. Enzon Reports Second Quarter Financial Results; Sales of Marketed ......
Business Editors/Health/Medical WritersBRIDGEWATER, N.J.--(BUSINESS WIRE)--Feb. 4, 2004Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) announced today its
financial results for the quarter ended December 31, 2003, the second
quarter of Enzon's fiscal year (FY) 2004. The C...
08. Enzon to Present at Bear Stearns 20th Annual Healthcare Conference ......
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN)
announced today that Jeffrey H. Buchalter, Enzon's chairman and
chief executive officer, will present at the Bear Stearns 20th Annual
Healthcare Conference, which is being held September 10-11 in New...
09. Enzon Reports Second Quarter Results and Transitions to Calendar Year ...
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN)
today announced its financial results for the quarter ended December 31,
2005, the second quarter of Enzon's six-month transition period
ended December 31, 2005. As previously reported, Enzon announced...
10. Enzon Reports Significant Progress on the Reduction of Its Debt ......
Only $12.5 million in 2008 debt remaining
...
11. Jack Geltosky, Ph.D. Joins Enzon's Board of Directors | Business Wire ...
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Dr. Jack Geltosky has been appointed to the Company's Board of Directors.
...
12. Enzon Eliminates Its Remaining 2008 Debt | Business Wire | Find ......
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today it has successfully eliminated all of its remaining 2008 debt.
...
13. Enzon Reports Four-Fold Increase in Second Quarter Earnings | Business...
Business Editors & Health/Medical Writers
...
14. Enzon Stockholders Approve Company Proposals at 2008 Annual Meeting .....
BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) held its annual meeting of stockholders today in Indianapolis, IN. At the meeting, the Company's stockholders voted to approve several key issues proposed by Enzon, including:
...
15. Enzon to Webcast Live from Investor Day in NYC | Business Wire | Find ...
-- Company to provide pipeline update and 3(rd) quarter earnings --
...
16. Enzon Reports Third Quarter Fiscal Year 2000 Financial Results ......
Business & Health Editors
...
17. Drug for children with rare disease - PEG-ADA to treat severe combined...
A newly approved drug offers hope for children with severe combined immunodeficiency disease (SCID), which affects about 40 children a year worldwide. These children lack adequate immune defenses and usually die from infections before they are 2 years old.
...
18. Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ......
Study to examine safety and tolerability in solid tumors and lymphoma
...
19. Enzon Reports Fourth Quarter and Fiscal Year Results For 2000 ...
Business & Health Editors
...
